Clinical trials: Hemostatic Agents
Multiple Myeloma
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38…
- Trial name
- NCT05217082
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma.
- Trial name
- NCT00131261
- Testing
- PXD101, Dexamethasone
- Where
- 10 sites in United States, Denmark and 2 more
- Volunteers
- 25 people
- Sponsor
- Valerio Therapeutics
Multiple Myeloma
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
This is a multi-center, open-label, single arm, non-comparative phase II trial, designed to evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with Multiple Myeloma (MM) double…
- Trial name
- NCT03117361
- Testing
- plitidepsin, Bortezomib, Dexamethasone
- Where
- 13 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- PharmaMar
PATIENTS WITH UNEXPLAINED BLEEDING DISORDERS
Innovative Approaches to Identify Causative Genetic Variants in Patients With Unexplained Bleeding Disorders
Creation of an Italian network for unexplained bleeding disorders, using integrated multi-omics approaches to improve diagnosis, optimize patient management, and identify novel therapeutic targets.
- Trial name
- UNEX-EMO 2022 (NCT07870057)
- Where
- Italy
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Reversal of Coagulopathy
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by vitamin K antagonists in subjects who require…
- Trial name
- BE1116_3003 (NCT00803101)
- Testing
- Beriplex® P/N (Kcentra), Fresh frozen plasma
- Where
- 30 sites in United States, Belarus and 4 more
- Volunteers
- 176 people
- Sponsor
- CSL Behring
Multiple Myeloma
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells
To evaluate the overall response rate, safety, and the 12-cycle clearance rate of circulating plasma cells (CPCs) in patients with newly diagnosed transplant-ineligible multiple myeloma stratified as high-risk based on…
- Trial name
- NCT07732712
- Testing
- Isatuximab, VRD
- Volunteers
- 15 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT06083207
- Testing
- IBI3003
- Where
- 13 sites in Australia, China
- Volunteers
- 116 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Peripheral Revascularisation
Optimized Heparin Regimen in Vascular Surgery
Hypothesis: Optimal anticoagulation defined as an Activated Clotting Time (ACT) of 300 to 350 seconds obtained by weight-adjusted doses of unfractionated heparin (UFH) will improve the hemostatic environment downstream from the…
- Trial name
- NCT02477072
- Testing
- ACT, TEG, Ankle-brachial index
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Multiple Myeloma
Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma
The present trial is designed as a phase II study that aims at estimating the efficacy of the combination of bendamustine, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The response rate, i.e.
- Trial name
- BVD (NCT01045681)
- Testing
- Bendamustine, Velcade and Dexamethasone
- Where
- 37 sites in France
- Volunteers
- 75 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability and to establish the maximum tolerated dose of JNJ-26481585 combined with VELCADE and dexamethasone.
- Trial name
- NCT01464112
- Testing
- JNJ-2641585 / VELCADE / Dexamethasone
- Where
- 3 sites in France
- Volunteers
- 18 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Plasma Cell Neoplasm
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00547365
- Testing
- Human immune globulin intravenous (IGIV)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Tennessee
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
The reconstitution of a functioning immune system after allogeneic stem cell transplantation takes months to years. Particularly memory B-lymphocytes reconstitute poorly with the current conditioning regimes.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non Hodgkin's Lymphoma
- Trial name
- B-cell therapy (NCT02007811)
- Testing
- allogeneic donor derived B-lymphocytes
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
The purpose of this study is to determine whether ublituximab in combination with lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies who have relapsed or are refractory after CD20…
- Conditions
- Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas
- Trial name
- NCT01744912
- Testing
- Ublituximab, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- TG Therapeutics, Inc.
Coagulopathy, Congenital Heart Disease
FFP Usage in Pediatric CV Surgery
When small children undergo heart surgery with the heart-lung machine, in the past, blood products to help the blood clot such as Fresh Frozen Plasma (FFP) was routinely used in children under 10kg.
- Trial name
- NCT05819788
- Where
- Canada
- Volunteers
- 431 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Multiple Myeloma (MM)
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
This is a prospective, single-arm, exploratory Phase II clinical study evaluating the efficacy and safety of HP-001 capsules in combination with dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) with…
- Trial name
- BEYOND-MM 001 (NCT07811986)
- Testing
- HP-001, Dexamethasone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
No Placental Abruption, No Hemorrhage
Proof of Concept Study of a Sucker Hemostatic Intra Uterine in Postpartum Hemorrhage After Abruptio Placenta Assisted
The postpartum hemorrhage (PPH) is the major complication of the delivery. In clinical practice, if after giving birth, the placenta is not expelled naturally, an active management should be triggered.
- Trial name
- HEMOGYN (NCT01589744)
- Testing
- Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)
- Where
- France
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- AdministrateurCIC
Multiple Myeloma
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
This study will compare the effectiveness and safety of maintenance therapy with continuous bortezomib, lenalidomide, and dexamethasone (VRD) compared to maintenance therapy that alternates VRD with Elotuzumab, lenalidomide, and…
- Trial name
- NCT03000634
- Testing
- Elotuzumab, Bortezomib, Lenalidomide
- Sponsor
- University of Arkansas
Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
This trial is a Multiple center, Open-label, dose escalation Phase Ⅰ clinical study. The purpose is to evaluate the safety and tolerability of F182112 when infused intravenously (IV) and determine the maximum tolerated dose (MTD)…
- Trial name
- NCT04984434
- Testing
- F182112
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
Leukemia
A Study in Leukemia Patients With Karonudib
The primary objective of this study is to determine safety and tolerability of Karonudib for the treatment of hematological malignancies.
- Trial name
- MAATEO (NCT04077307)
- Testing
- Karonudib
- Where
- 7 sites in Denmark, Serbia and 1 more
- Volunteers
- 50 people
- Sponsor
- Thomas Helleday Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.